Compare ASAN & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASAN | ZYME |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2020 | 2022 |
| Metric | ASAN | ZYME |
|---|---|---|
| Price | $8.90 | $25.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 11 |
| Target Price | $12.46 | ★ $38.90 |
| AVG Volume (30 Days) | ★ 5.2M | 408.6K |
| Earning Date | 06-02-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.93 | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $790,806,000.00 | $105,965,000.00 |
| Revenue This Year | $10.19 | $183.10 |
| Revenue Next Year | $7.91 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 9.25 | ★ 38.87 |
| 52 Week Low | $5.38 | $13.48 |
| 52 Week High | $15.71 | $29.75 |
| Indicator | ASAN | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 60.86 | 61.35 |
| Support Level | $5.77 | $22.10 |
| Resistance Level | $9.34 | $26.92 |
| Average True Range (ATR) | 0.52 | 0.97 |
| MACD | 0.07 | 0.33 |
| Stochastic Oscillator | 73.77 | 94.47 |
Asana Inc is the system of action for work, built for the Agentic Enterprise. It provides a comprehensive solution where humans and AI agents can collaborate effectively so that individuals work smarter, teams move faster, and organizations deliver results. Companies use Asana to connect their work to company goals and orchestrate mission-critical workflows like product launches, employee onboarding, resource planning, tracking company-wide strategic initiatives and more. It manages its operations and allocates resources as a single operating and reportable segment. The company generates revenues from subscriptions from paying customers accessing its cloud-based platform.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.